Charlotte van Kesteren
Overview
Explore the profile of Charlotte van Kesteren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Langenhorst J, Dorlo T, van Kesteren C, Van Maarseveen E, Nierkens S, de Witte M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2020 Jan;
9(5):272-281.
PMID: 31957334
Optimal fludarabine exposure has been associated with improved treatment outcome in allogeneic hematopoietic cell transplantation, suggesting potential benefit of individualized dosing. A randomized controlled trial (RCT) comparing alternative fludarabine dosing...
12.
Admiraal R, Jol-van der Zijde C, Furtado Silva J, Knibbe C, Lankester A, Boelens J, et al.
Clin Pharmacokinet
. 2019 May;
58(12):1609-1620.
PMID: 31131436
Background And Objective: Alemtuzumab (Campath) is used to prevent graft-versus-host disease and graft failure following pediatric allogeneic hematopoietic cell transplantation. The main toxicity includes delayed immune reconstitution, subsequent viral reactivations,...
13.
Schoemakers R, van Kesteren C, van Rosmalen J, Eussen M, Dieleman H, Beex-Oosterhuis M
J Child Adolesc Psychopharmacol
. 2019 Jan;
29(3):192-196.
PMID: 30672720
Background: Weight gain due to the use of second-generation antipsychotics is a major health care issue for adult and paediatric psychiatric patients. Little is known about long-term weight gain effects...
14.
de Koning C, Langenhorst J, van Kesteren C, Lindemans C, Huitema A, Nierkens S, et al.
Biol Blood Marrow Transplant
. 2018 Oct;
25(4):819-826.
PMID: 30359735
Innate immune cells are the first to recover after allogeneic hematopoietic cell transplantation (HCT). Nevertheless, reports of innate immune cell recovery and their relation to adaptive recovery after HCT are...
15.
Langenhorst J, Dorlo T, Van Maarseveen E, Nierkens S, Kuball J, Boelens J, et al.
Clin Pharmacokinet
. 2018 Oct;
58(5):627-637.
PMID: 30327943
Background: Fludarabine is often used as an important drug in reduced toxicity conditioning regimens prior to hematopoietic cell transplantation (HCT). As no definitive pharmacokinetic (PK) basis for HCT dosing for...
16.
Punt A, Langenhorst J, Egas A, Boelens J, van Kesteren C, Van Maarseveen E
J Chromatogr B Analyt Technol Biomed Life Sci
. 2017 Apr;
1055-1056:81-85.
PMID: 28445850
In allogeneic hematopoietic cell transplantation (HCT) it has been shown that over- or underexposure to conditioning agents have an impact on patient outcomes. Conditioning regimens combining busulfan (Bu) and fludarabine...
17.
Admiraal R, Nierkens S, de Witte M, Petersen E, Fleurke G, Verrest L, et al.
Lancet Haematol
. 2017 Mar;
4(4):e183-e191.
PMID: 28330607
Background: Anti-thymocyte globulin (ATG) is used to prevent graft-versus-host disease (GvHD) after allogeneic haemopoietic cell transplantation (HCT). However, ATG can also cause delayed immune reconstitution of T cells, negatively affecting...
18.
Admiraal R, Lindemans C, van Kesteren C, Bierings M, Versluijs A, Nierkens S, et al.
Blood
. 2016 Oct;
128(23):2734-2741.
PMID: 27702800
Successful immune reconstitution (IR) is associated with improved outcomes following pediatric cord blood transplantation (CBT). Usage and timing of anti-thymocyte globulin (ATG), introduced to the conditioning to prevent graft-versus-host disease...
19.
Admiraal R, van Kesteren C, Nierkens S, Boelens J
J Allergy Clin Immunol
. 2016 May;
138(2):633.
PMID: 27212085
No abstract available.
20.
Admiraal R, van Kesteren C, Jol-van der Zijde C, Lankester A, Bierings M, Egberts T, et al.
Lancet Haematol
. 2015 Dec;
2(5):e194-203.
PMID: 26688094
Background: Anti-thymocyte globulin (ATG) was introduced into the conditioning regimen in haemopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. However, ATG can also cause delayed immune reconstitution...